View Older Stories View More Recent Stories
-
Merck (MRK) Reports Positive Topline Results From the First Two Phase 3 CORALreef Trials
-
BMO Capital on Merck (MRK): 'Long-Term Plan, Short-Term Challenges'
-
Goldman Sachs Reiterates Buy Rating on Merck (MRK)
-
Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT
-
Merck (MRK) Announces MK-1084 Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
-
Merck's (MRK) Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate
-
Citizens JMP shares updates on cancer treatment stocks
-
Merck (MRK) Declares $0.81 Quarterly Dividend; 4.2% Yield
-
What can get the U.S. large-cap pharma sector to work?
-
Merck's (MRK) EMD Serono to present new oncological data at ASCO 2025
-
Merck's (MRK) EMD Serono announces positive Enpatoran data
-
UBS Reiterates Buy Rating on Merck (MRK)
-
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
-
Merck (MRK) Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival
-
Merck (MRK) announces FDA approval of WELIREG
-
Citi Downgrades Merck (MRK) to Neutral
-
Evercore ISI Reiterates Outperform Rating on Halozyme Therapeutics (HALO)
-
Trump to pitch sweeping Medicare drug price plan - Politico
-
Merck (MRK) call put ratio 1 call to 1.3 puts
-
What is the impact of U.S. tariffs on biopharma sector?
-
Kuehn Law Encourages Investors of Merck & Co., Inc. to Contact Law Firm
-
WHO to Back Use of Weight-loss Drugs for Adults Globally, Raises Cost Issue - Reuters
-
Amazon (AMZN) Comments Circulate
-
Merck (MRK) PT Lowered to $108 at Guggenheim
-
Merck (MRK) Breaks Ground on New $1B Biologics Center of Excellence in Wilmington, Delaware
-
Merck to Spend $1 Billion on New Factory to Make US Supplies of Blockbuster Drug - WSJ
-
Merck Kgaa To Buy Springworks For $47 Per Share In Cash- Bloomberg
-
Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation
-
Merck (MRK) Tops Q1 EPS by 8c; updates guidance
-
Merck & Co. Q1 preview: Here’s what Wells Fargo expects to see
-
Merck (MRK) call put ratio 1.2 calls to 1 put into quarter results
-
Merck (MRK) call put ratio 2.2 calls to 1 put into quarter results
-
Cantor Fitzgerald Starts Merck (MRK) at Neutral
-
UBS Reiterates Buy Rating on Merck (MRK)
-
MRK IMPORTANT DEADLINE: ROSEN, A LEADING NATIONAL FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important April 14 Deadline in Securities Class Ac
-
MRK FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
-
Pharma stocks slide after Trump signals tariffs on sector
-
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
MRK DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action - MRK
-
Goldman Sachs Assumes Merck (MRK) at Buy
-
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
-
MRK FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Clas
-
MRK FINAL DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Actio
-
MRK FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action - M
-
UBS Reiterates Buy Rating on Merck (MRK)
-
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK
-
Bernstein Assesses U.S. Biopharma Stocks Amid Tariff Risks
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co.
-
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRK

